Lori Leskin Speaks with The New York Times on New FDA Guidance for Social Media Use by Drug Companies
As Seen in The New York Times’ “FDA Proposes Rules for Listing Risks on Social Media”
The New York Times reports that the FDA issued a set of proposed rules on Tuesday that would require pharmaceutical and medical device companies to list the risks of their products in Twitter feeds if benefits are also mentioned. The rules would to other social media platforms that similarly limit message length. The guidelines also allow these industries to fix any information posted by third parties that could be seen as false or misleading.
According to Kaye Scholer Life Sciences Partner Lori Leskin, companies have hesitated to use Facebook and Twitter in the past due to uncertainty in the FDA rules and for fear of censure.
Also of Interest
- And Now A Word From The Panel: 3 Alternatives To MDLs September 28, 2016 • Articles
- Kaye Scholer Represents Investors in Volkswagen Diesel Emissions Litigation September 28, 2016 • Client Successes
- NLJ Names Shores as Antitrust Trailblazer September 27, 2016 • Recognitions
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Druckenbrodt Quoted in Bloomberg on Volkswagen Dieselgate September 14, 2016 • Media Mentions
- Arbisser Featured in The Recorder and Law360... September 7, 2016 • Media Mentions
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- ILS and Zinsser Analytic Shareholders Sell to Gardner Denver Medical September 2, 2016 • Client Successes